<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002949</url>
  </required_header>
  <id_info>
    <org_study_id>8270</org_study_id>
    <secondary_id>UCCRC-8270</secondary_id>
    <secondary_id>NCI-G97-1156</secondary_id>
    <nct_id>NCT00002949</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis</brief_title>
  <official_title>Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining radiation therapy with chemotherapy with may kill more
      tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and
      paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the
      pelvis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the toxic effects of vinorelbine given on a weekly schedule combined
      with standard whole pelvic radiation therapy. II. Determine the Maximum Tolerated Dose (MTD)
      of vinorelbine given on a weekly schedule combined with standard whole pelvic radiation
      therapy. III. Access the toxic effects of paclitaxel given weekly in combination with the
      regimen determined to be the MTD of vinorelbine. IV. Determine the MTD of paclitaxel given
      weekly in combination with the regimen determined to be the MTD of vinorelbine.

      OUTLINE: Part I: Vinorelbine IV bolus is administered over 8-10 minutes on day 1 prior to
      radiation therapy. Whole pelvic radiation treatment is given on days 1-5 followed by 2 days
      of rest. The treatment volume encompasses all suspected pelvic disease with a minimum of 1 cm
      margin. Cycles repeat weekly. Dose of vinorelbine is escalated in cohorts of at least 3
      patients until maximum tolerated dose (MTD) is determined. Part II: Paclitaxel is infused
      over 1 hour immediately following vinorelbine at the MTD, as determined in part I. Dose of
      paclitaxel is escalated in cohorts of at least 3 patients until the MTD is determined. At
      least 6 patients are treated at the MTD for both parts I and II of the study. Patients are
      followed for late and chronic toxicities.

      PROJECTED ACCRUAL: Projected accrual is 12 patients per year for approximately 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">November 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed locally advanced carcinoma of the uterine
        cervix, vagina, or bladder or other pelvic malignancy for which whole pelvic radiation
        therapy is planned Metastatic disease is permitted

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: CALGB 0-2 Hematopoietic: WBC at
        least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin within normal limits
        Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: No unstable angina or
        myocardial infarction in previous 6 months Other: Not pregnant No significant concomitant
        illness, uncontrolled infection, or cirrhosis

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior whole pelvic radiation
        therapy Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini F. Fleming, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2004</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>stage II vaginal cancer</keyword>
  <keyword>stage III vaginal cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

